Nov 10, 2009 by Brian Orelli, PhD3 Companies Looking for Gratitude EarlyTheir drugs will have to get past the FDA first.
Nov 10, 2009 by Brian Orelli, PhDSmall Acquisitions and the Road to SuccessBristol-Myers is taking a different route to bulk up.
Nov 9, 2009 by Brian Orelli, PhDHealth-Care Reform: A Tale of Two ChambersHalfway done, but the battle is just heating up.
Nov 4, 2009 by Brian Orelli, PhDThis One Is Thriving in a RecessionSaving customers money makes it easy for Medco.
Nov 3, 2009 by Brian Orelli, PhDA Little Distracted, Are You, Merck?The FDA rejects its latest application.
Nov 3, 2009 by Brian Orelli, PhDNice Quarter, Teva. What Will You Buy Next?Branded or generic, it's always a tough call.
Nov 2, 2009 by Brian Orelli, PhDFinally Convinced? Benlysta Works!Human Genome Sciences succeeds where others have failed.
Nov 2, 2009 by Brian Orelli, PhDWinners and Losers of the House Health-Care Reform BillThere's something for everyone to hate.
Oct 30, 2009 by Brian Orelli, PhDCome On -- They Represent Your Mom!A fight with AARP proves that we're seeing politics as usual.
Oct 30, 2009 by Brian Orelli, PhDWorld's Scariest Stocks: PfizerIt may be a known unknown, but it still gives me the willies.
Oct 30, 2009 by Brian Orelli, PhDOf One-Time Gains and PipelinesAstraZeneca had some of both during the third quarter.
Oct 30, 2009 by Brian Orelli, PhDIt's Not As Frightening As It First AppearsWarning: generic adjustments ahead.
Oct 30, 2009 by Brian Orelli, PhDEarnings? Yawn. Trial Data? Moving!For Human Genome Sciences investors, the anticipation is frightening.
Oct 30, 2009 by Brian Orelli, PhDShrugging Off the Side EffectsSanofi is looking good, but still faces the loss of Lovenox.
